[No relation between angiotensin-converting enzyme (ACE) inhibitor-induced cough and ACE gene polymorphism, plasma bradykinin, substance P and ACE inhibitor concentration in Japanese patients].
Persistent dry cough is well known as the most common side-effect of angiotensin-converting enzyme (ACE) inhibitors. We examined the relationship between a cough and ACE gene polymorphism, plasma bradykinin (BK), substance P (SP) and ACE inhibitor concentrations in patients with hypertension or chronic nephritis. First, ACE genotyping was carried out in 96 patients, 42 with coughs and 54 without coughs, which had been treated with various kinds of ACE inhibitors. However, no significant difference in the ACE genotypes was observed between the two groups. Second, the plasma concentrations of BK, SP and ACE inhibitor were measured in 12 patients, which were treated with trandolapril at a daily dose of 1 mg for 4-33 weeks. In 3 patients, the cough was induced during the trandolapril therapy, while it was induced not in 9 patients. The plasma levels of BK and SP did not significantly change after trandolapril administration in the patients with and without coughs. Between the two groups, there were no significant differences in the plasma levels of BK and SP either before or after the trandolapril therapy. Also the plasma concentrations of trandolapril and trandolaprilat, the active metabolite of trandolapril, did not significantly differ between the two groups. These results suggest that there is no significant relationship between the ACE inhibitor-induced cough and ACE gene polymorphism, plasma BK, SP and ACE inhibitor concentrations in patients with hypertension or chronic nephritis.
Department of Hospital Pharmacy, Tokyo Postal Services Agency Hospital, 2-14-23 Fujimi, Chiyoda-ku, Tokyo 102-8798, Japan.
H
H
Okumura
E
E
Nishimura
S
S
Kariya
M
M
Ohtani
K
K
Uchino
T
T
Fukatsu
J
J
Odanaka
T
T
Takahashi
K
K
Watanabe
T
T
Itoh
M
M
Hashiguchi
H
H
Echizen
T
T
Rikihisa
D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects* / Q000097:blood; D001920:Bradykinin / Q000097:blood*; D002908:Chronic Disease; D003371:Cough / Q000139:chemically induced*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007211:Indoles / Q000009:adverse effects* / Q000097:blood; D008297:Male; D008875:Middle Aged; D009393:Nephritis / Q000188:drug therapy; D007703:Peptidyl-Dipeptidase A / Q000235:genetics*; D011110:Polymorphism, Genetic; D013373:Substance P / Q000097:blood*
D000806:Angiotensin-Converting Enzyme Inhibitors; D007211:Indoles; C052035:trandolapril; D013373:Substance P; D007703:Peptidyl-Dipeptidase A; D001920:Bradykinin